180 Life Sciences Company Overview
About 180 Life Sciences
180 Life Sciences (NASDAQ:ATNF) is a biotechnology company focused on the development of novel therapies to combat inflammation, fibrosis, and pain. Operating at the cutting edge of medical research, their projects range from preclinical to Phase 2 clinical trials across various indications. These include addressing diseases such as Dupuytren’s contracture, Frozen shoulder, and Post-surgical pain, aiming to meet significant unmet medical needs. The objectives of 180 Life Sciences revolve around advancing these pioneering treatments through rigorous testing, aligning with regulatory approvals to eventually bring transformative solutions to patients globally. With a commitment to innovative science and patient well-being, they aim to lead advancements in biotechnology and therapeutic discovery.
Snapshot
Operations
Products and/or services of 180 Life Sciences
- Development of anti-TNF therapies aimed at treating inflammation, focusing on Dupuytren's contracture.
- Research on fibrosis and anti-tumor necrosis factor (TNF) treatments for various indications.
- Clinical trials investigating treatments for frozen shoulder, a condition related to Dupuyren's contracture.
- Expansion into cannabinoid-based therapeutics for addressing pain and inflammation.
- Advancements in synthetic CBD compounds for treating inflammatory diseases.
- Collaborations and partnerships for the development and distribution of novel therapeutics.
180 Life Sciences executive team
- Mr. Lloyd Blair Jordan L.L.B., M.B.A.CEO & Director
- Sir Marc Feldman Ph.D.Co-Founder
- Mr. McAndrew Rudisill BA(Econ)Executive Chairman
- Prof. Jagdeep Nanchahal M.D., Ph.D.Co-Founder & Chairman of Clinical Advisory Board
- Mr. Eric R. Van LentCAO, Principal Accounting & Financial Officer